Research: CARRARO and colleagues, P

Listed in Issue 19

Abstract

CARRARO and colleagues, Perre Fabre Medicament, La Chartreuse, Castres, France, noting the controversy regarding the relative efficacy of treatments for the relief of symptoms of benign prostatic hyperplasia (BPH), compared the use of 320 mg plant extract Permixon with 5 mg finasteride, a 5-alpha-reductase inhibitor, in the treatment of BPH.

Background

Methodology

The authors conducted a 6-month double-blind randomised study with more than 1000 men with moderate BPH, using the criteria of the International Prostate Symptom Score (IPSS) as the primary end-point.

Results

Both Permixon and finasteride decreased the IPSS (-37% and -39%) , improved the quality of life (38% and 41%) and increased peak urinary flow rate (+25% and +30%). Finasteride markedly decreased prostate volume (-18%) and serum PSA levels (-41%). Permixon improved symptoms with little effect upon volume (-6%) and no change in PSA levels. Permixon was superior to finasteride in a sexual function questionnaire and give rise to fewer complaints of decreased libido and impotence.

Conclusion

Both treatments relieve BPH treatments in two-thirds of patients. Permixon, unlike finasteride, has little effect upon so-called androgen-dependent parameters, suggesting that other pathways may also be involved in BPH symptomatology.

References

Carraro JC et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 29(4): 231-40. Oct 1996.

Munro Hall Clinic 2019

IJCA 2018 New Skyscraper

Scientific and Medical Network 2

Royal Rajasthan Cycle 2021

Amazon Wilderness Trek 2022

Cycle Kilimanjaro to the Coast 2022

top of the page